Trial Profile
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 238
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 7 years updated results presented at the 48th European Society for Medical Oncology Congress.
- 12 Oct 2023 According to Bristol Myers Squibb media release, data from this study will be presented at ESMO 2023.
- 19 Jul 2023 Results assessing patient outcomes and safety profile published in the European Journal of Cancer